Navigation Links
NeoGenomics, Inc. Reports First Quarter 2009 Financial Results

Revenue and Gross Margin Increases, Company Achieves Profitability

FT. MYERS, Fla., April 23 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter ended March 31, 2009.

First Quarter 2009 Highlights:

  • Revenue of $6.9 million, an increase of 66% year-over-year from Q1 08
  • 16.8% sequential increase in revenues from Q4 08
  • 55.3% gross margin up from 53.1% in Q4 08
  • 9.8% sequential increase in Avg. Revenue/Requisition to $900 from $820 in Q4 08
  • 6.0% sequential increase in Avg. Revenue/Test to $661 from $624 in Q4 08
  • SG&A expenses declined to 53.2% of revenue from 56.1% in Q4 08

Sequential Comparisons (Q1 09 vs. Q4 08)

On a sequential basis, our revenues increased approximately $1.0 million or 16.8% to $6.9 million in Q1 09 from Q4 08. This was driven by a 10.2% increase in the number of tests completed and a 6.0% increase in the average revenue/test vs. Q4 08. Our average revenue/requisition increased by 9.8% to $900. Gross profit margin increased to 55.3% in Q1 09 from 53.1% in Q4 08, which resulted in a $680,000 or 21.6% overall increase in gross profit from Q4 08. Our selling, general and administrative (SG&A) expenses increased by approximately $354,000 or 10.7% in Q1 09 from the normalized SG&A expense level in Q4 08 which adjusts for the $518,000 of write-offs we took in Q4 08 in connection with expensing previously capitalized items. SG&A as a percentage of revenue decreased to 53.2% in Q1 09 from 56.1% (as adjusted) in Q4 08. Net income in Q1 09 increased by approximately $1.0 million to $33,000 or $0.00/share from ($994,000) or ($0.03)/share in Q4 08.

Douglas VanOort, the Company's Executive Chairman and Interim Chief Executive Officer, said, "Having been with NeoGenomics for five weeks now, I am even more impressed with the Company and its opportunities than when I first joined. I am particularly pleased with the revenue growth in Q1 and the fact that we were able to achieve profitability despite the significant investments we made in our sales team and operations during the quarter. We have an excellent foundation in place as we begin to move into the next phase of our development."

During the first quarter, volume increases were driven primarily by an increase in our sales force and higher productivity from our sales representatives. Increases in average revenue per test resulted from increases in the Medicare reimbursement levels in 2009 for several of our core testing platforms including both flow cytometry and FISH, and to a lesser extent, from a higher percentage of flow cytometry testing in our mix.

Robert Gasparini, the Company's President and Chief Scientific Officer, commented further, "The first quarter was very strong for us on multiple fronts. We experienced the largest sequential increase in revenues in our company's history, increased our gross margin, and most importantly, we turned profitable. In addition, increases in our SG&A during Q1 were modest relative to our revenue growth with approximately 90% of this increase dedicated to additional investments in our sales and marketing activities. We believe this combination of increased revenue and gross margin coupled with our ability to leverage our SG&A demonstrates the significant operating leverage we have begun to realize in our business."

In January, Medicare appended its policies with respect to the reimbursement procedures for a wide variety of laboratory tests including certain FISH, flow cytometry and immunohistochemistry tests in an effort reduce costly payment errors and ensure they are paying for the appropriate services. These changes impacted the lab industry nationally and resulted in an inordinate amount of denials within the industry. Most of these edits have now been suspended while talks between the Centers for Medicare and Medicaid Services (CMS) and industry representatives are ongoing to correct the problems. Some of the test codes we use were caught up in these edits, which resulted in approximately $500,000 of our Q1 Medicare claims being denied. We have since modified our billing procedures and appealed these denials as recommended. While we expect that we will be paid on substantially all of these claims over time, as a result of the initial denials, our accounts receivable at March 31, 2009 is approximately $500,000 higher than it otherwise would have been. This, in turn, lowered our cash flow from operations in Q1 by approximately $500,000. We view this as a timing issue, and we expect this trend to reverse itself in Q2 and Q3 as our appeals are adjudicated.

Year-Over-Year Comparisons (Q1 09 vs. Q1 08)

On a year-over-year basis, revenues increased by $2.8 million or 66.0% to $6.9 million in Q1 09 from $4.2 million in Q1 08. Tests increased by 54.7% and the average revenue/test increased 7.3%. Requisitions increased by 42.1% and average revenue/requisition increased by 16.9%. Gross profit margin in Q1 09 was 55.3% which was essentially flat vs. 55.4% in Q1 08. Selling, general and administrative (SG&A) expenses increased by 46.2%, but SG&A as a percentage of revenue fell to 53.2% in Q1 09 from 60.4% in Q1 08. Net income in Q1 09 increased by approximately $299,000 to $33,000 or $0.00/share from ($265,000) or ($0.01)/share in Q1 08.

Conference Call

The Company has scheduled a webcast and conference call to discuss their Q1 2009 results at 11:00 AM EST today. Interested investors should dial (877) 407-9210 (domestic) and (201) 689-8049 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on May 6, 2009 and can be accessed by dialing (877) 660-6853 (domestic) and 1(201) 612-7415 (international). The playback conference ID Number is 320759 and the PIN Number is 286. The web-cast may be accessed under the Investor Relations section of our website at or at . An archive of the web-cast will be available until 11:59 PM EST on April 23, 2010.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit

For more news and information on NeoGenomics, please visit where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at or from the American Microcap Institute at

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

                                    NeoGenomics, Inc.

                           CONSOLIDATED BALANCE SHEETS AS OF
                         March 31, 2009 and December 31, 2008

    ASSETS                                March 31, 2009    December 31, 2008

      Cash and cash equivalents               $857,190          $468,171

      Accounts Receivable (net of allowance
         for doubtful accounts of $474,337
         and $358,642, respectively)         3,955,266         2,913,531

      Other Current Assets                   1,074,888           973,867

    TOTAL CURRENT ASSETS                     5,887,344         4,355,569

    PROPERTY AND EQUIPMENT (net of accumulated
       depreciation of $1,839,653 and
       $1,602,594, respectively)             2,857,025         2,875,297

    OTHER ASSETS                                72,791            64,509

        TOTAL                               $8,817,160        $7,295,375


    CURRENT LIABILITIES                     $5,152,506        $4,390,995

    LONG TERM LIABILITIES                    1,371,334         1,403,271

        TOTAL LIABILITIES                    6,523,840         5,794,266

    STOCKHOLDERS' EQUITY                     2,293,320         1,501,109

       TOTAL                                $8,817,160        $7,295,375

                                NeoGenomics, Inc.


                                             For the        For the
                                          Three-Months   Three-Months
                                              Ended          Ended
                                            March 31,      March 31,
                                              2009           2008

    REVENUE                                $6,913,520     $4,162,762

    COST OF REVENUE                         3,090,442      1,858,474

    GROSS PROFIT                            3,823,078      2,304,288

    Selling, general and administrative     3,675,084      2,514,555

    Income (loss) from operations             147,994       (210,267)

    Other income (loss) -
    Interest income/(expense), net           (114,816)       (55,096)

    NET INCOME (LOSS)                         $33,178      $(265,363)

    - Basic                                     $0.00         $(0.01)
    - Diluted                                   $0.00         $(0.01)

    - Basic                                32,173,698     31,400,947
    - Diluted                              35,630,058     31,400,947

                                     NeoGenomics, Inc.


                                              For the          For the
                                           Three-Months      Three-Months
                                              Ended             Ended
                                             March 31,        March 31,
                                               2009             2008

     OPERATING ACTIVITIES                   $(331,538)        $194,638

    NET CASH USED IN INVESTING ACTIVITIES      (5,886)         (25,115)

     FINANCING ACTIVITIES                     726,443          (49,738)

           EQUIVALENTS                        389,019          119,785

     OF PERIOD                                468,171          210,573

     PERIOD                                  $857,190         $330,358


      Interest paid                          $100,391          $47,931

      Income taxes paid                      $      -          $     -


      Equipment leased under capital lease   $178,837         $162,043

      Equipment purchased and included in
       accounts payable at March 31, 2008      46,250           33,713

                                      NeoGenomics, Inc.

                 Supplemental Information on Customer Requisitions Received
                                    and Tests Performed

                                   For the          For the
                                Three-Months     Three-Months
                                    Ended            Ended
                               March 31, 2009   March 31, 2008   % Inc (Dec)

    Requisitions Rec'd (Cases)      7,681           5,405          42.1%
    # of Tests Performed           10,457           6,759          54.7%
    Avg. # of Tests / Case           1.36            1.25           8.8%

    Testing Revenue            $6,913,520      $4,162,762          66.1%
    Avg Revenue/Requisition       $900.08         $770.17          16.9%
    Avg Revenue/Test              $661.14         $615.88           7.3%

SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
2. Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results
3. CuraGen Reports First Quarter 2009 Financial Results
4. NuVasive Reports First Quarter 2009 Financial Results
5. Torchmark Corporation Reports First Quarter 2009 Results
6. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
7. Kensey Nash Reports Third Quarter and First Nine Month Fiscal Year 2009 Results
8. WellPoint Reports First Quarter 2009 Results
9. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
10. Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
11. Schering-Plough Reports Financial Results for 2009 First Quarter
Post Your Comments:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset ... services to communities throughout the greater Pittsburgh metropolitan region, is joining forces with ... adaptive bicycles for differently-abled children. , Variety the Children’s Charity is a national ...
(Date:4/21/2017)... ... 2017 , ... The Hong Kong Polytechnic University (PolyU) launched today the University ... institutions in Hong Kong to support teaching, learning and research. It is also the ... facilities in Hong Kong. , With an area of 620 square metres and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California ... Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended ... and healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Westside Dental ... personalized dental care since 1985. After thirty-two years, Dr. Latner has become one of ... help my numerous clients over the years with all their dental needs,” said Dr. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By ... 2014 - 2025" report to their offering. ... The Latin American pharmaceutical contract ... by 2025 Low drug registration cost in Latin ...
(Date:4/19/2017)... -- Global Surgical Drainage Device Market: Overview ... excess liquid and air. The fluid to be drained ... Surgical drains are used in a wide variety of ... surgery, neurosurgery, plastic surgery etc. Common use of surgical ... fluid e.g. blood or pus. Surgical drains are available ...
Breaking Medicine Technology: